Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Bos
R
R
Gaubius Laboratory, IVVO-TNO, Leiden, The Netherlands.
Nieuwenhuizen
W
W
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D004337:Drug Carriers; D005337:Fibrin / Q000276:immunology / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D017395:Plasminogen Activator Inhibitor 1 / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D004337:Drug Carriers; D017395:Plasminogen Activator Inhibitor 1; D005337:Fibrin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator